Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Mach7 Technologies ( (AU:M7T) ) has shared an update.
Mach7 Technologies has announced the release of its Q4 FY25 financial results on 29 July 2025, followed by a webinar hosted by CEO Teri Thomas and CFO Dyan O’Herne. This event underscores Mach7’s commitment to transparency and engagement with the investment community, potentially impacting its market position and stakeholder relations.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.95 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
More about Mach7 Technologies
Mach7 Technologies (ASX:M7T) is a leading provider of medical imaging software, delivering advanced data management and diagnostic viewing solutions to healthcare organizations worldwide. The Mach7 Enterprise Imaging Solution (EIS) offers a flexible and scalable platform that includes a Vendor Neutral Archive (VNA), the eUnity Enterprise Diagnostic Viewer, and diagnostic workflow applications. Mach7 supports a diverse global network, including large integrated delivery networks, national health systems, independent provider groups, and private radiology practices.
Average Trading Volume: 247,257
Technical Sentiment Signal: Sell
Current Market Cap: A$82.24M
Find detailed analytics on M7T stock on TipRanks’ Stock Analysis page.